Severe Reactions Spur GlaxoSmithKline to Pull Batch of H1N1 Swine Flu Vaccine in Canada
Severe Reactions Spur GlaxoSmithKline to Pull Batch of H1N1 Swine Flu Vaccine in Canada
SUGAR LAND--December 4, 2009--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc (NYSE:GSK) (GSK) (Middlesex, England) has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure. The batch comprised 172,000 doses of the drug and had been distributed to health agencies in the provinces of Alberta, British Columbia, Manitoba, Ontario, Prince Edward Island and Saskatchewan.
Other companies featured: CSL Limited (ASX:CSL), (Victoria, Australia), Novartis AG (NYSE:NVS), Sanofi Aventis SA (NYSE:SNY), AstraZeneca plc (NYSE:AZN)
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market